SCHEMBL3576772

SCHEMBL3576772

CNN(Cc1ccc(C(F)(C(F)(F)F)C(F)(F)F)cc1)C(=O)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MLYCD O95822 2/20 0.48
HDAC1 Q13547 5/20 0.45
HDAC6 Q9UBN7 5/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
HDAC3 O15379 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44
HDAC10 Q969S8 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
LMNA P02545 1/20 0.43
NR1H2 P55055 1/20 0.42
NR1H3 Q13133 1/20 0.42
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 1/20 0.40
ATM Q13315 1/20 0.40
MTOR P42345 1/20 0.40
RORC P51449 1/20 0.40
NR1H4 Q96RI1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3576443 0.90 MLYCD (0.48) MLYCDHDAC1HDAC6MEN1KMT2A
SCHEMBL3583289 0.89 MEN1 (0.55) MLYCDHDAC1HDAC6MEN1KMT2A
SCHEMBL3576345 0.87 MLYCD (0.44) MLYCDHDAC1HDAC6MEN1KMT2A
SCHEMBL3580601 0.86 MLYCD (0.45) MLYCDHDAC1HDAC6MEN1KMT2A
SCHEMBL3586289 0.86 MLYCD (0.48) MLYCDLMNAALDH1A1RORC
SCHEMBL3572597 0.84 CTSS (0.46) MLYCDHDAC1HDAC6MEN1KMT2A
SCHEMBL3575045 0.81 SERPINE1 (0.47) MEN1KMT2ALMNANR1H4
SCHEMBL3571440 0.80 MLYCD (0.48) MLYCDHDAC1HDAC6MEN1KMT2A
SCHEMBL3580205 0.77 MEN1 (0.53) MEN1KMT2ALMNAATM
SCHEMBL3580095 0.72 HDAC6 (0.62) HDAC1HDAC6HDAC3HDAC7HDAC10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7678818-B2 Anthranilamide and 2-amino-heteroarene-carboxamide compounds HOFFMANN-LA ROCHE INC. (US) 2010-03-16 US disclosed
US-20070219261-A1 Anthranilamide and 2-amino-heteroarene-carboxamide compounds HOFFMANN-LA ROCHE INC. 2007-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219261-A1 Anthranilamide and 2-amino-heteroarene-carboxamide compounds AADAT, AAAS, AADAC MLYCD 1946/4885HDAC1 715/4885HDAC6 1130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.